Congratulations to Vannosi! The first original new drug was successfully approved for clinical use.

On July 2, 2020, fnx006 tablets, a new class I anti-tumor drug developed by Chengdu van Nux Biomedical Technology Co., Ltd., was approved and issued by the State Drug Administration (nmpa). The company will start phase I clinical trial in China.effect fnx006 is a new drug developed by Chengdu van Nux Biomedical Technology Co., Ltd., which is used to treat advanced malignant solid tumors such as triple negative breast cancer and melanoma.according to the results of preclinical studies, its antitumor activity is better than that of similar drugs.promote all colleagues of Chengdu van Nux under the leadership of president Liu Xiaoyu will do their best to promote the listing of fnx006 products, and provide safe, effective and reasonable therapeutic drugs for patients.Company Profile Chengdu van Nux Biomedical Technology Co., Ltd., located in Chengdu high tech Zone, is a high-tech enterprise specializing in innovative drug research, which was established in March 2017.the company has a number of innovative drug projects in the fields of cancer treatment, antiviral treatment, liver disease and so on, which are in different stages of preclinical research.the team members of the company are from well-known pharmaceutical companies at home and abroad such as GlaxoSmithKline, Lilly and Haizheng, with many years of experience in new drug research and development.Chengdu fanuoxi Biomedical Technology Co., Ltd. is willing to cooperate with people of insight, work hard, blaze new trails, strictly manage, and make due contributions to the medical and health undertakings of all mankind.